BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -47.49% | -39.54% | -79.73% | 4.81% | 24.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.39% | -54.10% | -80.18% | -17.75% | 1.69% |
| Operating Income | 46.39% | 54.10% | 80.18% | 17.75% | -1.69% |
| Income Before Tax | -164.32% | 65.31% | 90.35% | -5.08% | 399.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -164.32% | 65.31% | 90.35% | -5.08% | 399.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 126.58% | 9.38% | -104.11% | 104.90% | -322.96% |
| Net Income | -166.91% | 65.76% | 89.63% | 46.34% | 406.18% |
| EBIT | 46.39% | 54.10% | 80.18% | 17.75% | -1.69% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -155.88% | 72.41% | 91.13% | 52.38% | 361.54% |
| Normalized Basic EPS | -1,300.00% | 72.22% | 86.96% | 61.11% | 112.50% |
| EPS Diluted | -164.71% | 72.73% | 89.47% | 29.76% | 361.54% |
| Normalized Diluted EPS | -1,300.00% | 72.22% | 86.96% | 61.11% | 112.50% |
| Average Basic Shares Outstanding | 17.30% | 24.29% | 12.26% | 12.73% | 14.73% |
| Average Diluted Shares Outstanding | 3.48% | 24.29% | 12.26% | 12.73% | 30.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |